CERS - Cerus Update: Tailwinds Now Include FDA Approval Of Cryoprecipitate Product
- Cerus' FDA & CE approved Intercept pathogen reduction platform for platelets and plasma gathering momentum as FDA Guidelines require compliance with new blood safety measures by March 31, 2021.
- Cerus' plans to file for FDA extension of intercept platelet label from 5 to 7-day shelf life in 2021 should accelerate US-wide adoption of Intercept platelets.
- FDA recently approval Cerus' cryoprecipitate product, a $300 million product for the U.S. market.
- Cerus' Intercept Red Blood Cell product (largest component of worldwide $7 billion blood donor safety market) expects EU approval in 2022 followed by US approval in 2023/2024.
- Cerus currently has 1.5% of the potential world blood safety market with great potential to increase market share in years to come.
For further details see:
Cerus Update: Tailwinds Now Include FDA Approval Of Cryoprecipitate Product